What are the current recommended therapeutic ranges for COUMADIN® (Warfarin Sodium Tablets, USP) therapy?
The administration and dosage of COUMADIN® must be individualized for each patient according to the particular patient’s prothrombin time (PT)/International Normalized Ratio (INR) response to the drug. The dosage should be adjusted based upon the patient’s PT/INR.1 Venous Thromboembolism (including deep venous thrombosis [DVT] and pulmonary embolism [PE]): For patients with a first episode of DVT or PE secondary to a transient (reversible) risk factor, treatment with warfarin for 3 months is recommended. For patients with a first episode of idiopathic DVT or PE, warfarin is recommended for at least 6 to 12 months. For patients with two or more episodes of documented DVT or PE, indefinite treatment with warfarin is suggested. For patients with a first episode of DVT or PE who have documented antiphospholipid antibodies or who have two or more thrombophilic conditions, treatment for 12 months is recommended and indefinite therapy is suggested. For patients with a first episode of DVT or
Related Questions
- What should I know about the Vitamin K content of foods and COUMADIN® (Warfarin Sodium Tablets, USP) therapy?
- What are the current recommended therapeutic ranges for COUMADIN® (Warfarin Sodium Tablets, USP) therapy?
- What are some drug interaction considerations when taking COUMADIN® (Warfarin Sodium Tablets, USP)?
